HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates.

Abstract
Sepsis remains a major cause of mortality and morbidity in neonates, and, as a consequence, antibiotics are the most frequently prescribed drugs in this vulnerable patient population. Growth and dynamic maturation processes during the first weeks of life result in large inter- and intrasubject variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics. In this review we (1) summarize the available population PK data and models for primarily renally eliminated antibiotics, (2) discuss quantitative approaches to account for effects of growth and maturation processes on drug exposure and response, (3) evaluate current dose recommendations, and (4) identify opportunities to further optimize and personalize dosing strategies of these antibiotics in preterm and term neonates. Although population PK models have been developed for several of these drugs, exposure-response relationships of primarily renally eliminated antibiotics in these fragile infants are not well understood, monitoring strategies remain inconsistent, and consensus on optimal, personalized dosing of these drugs in these patients is absent. Tailored PK/PD studies and models are useful to better understand relationships between drug exposures and microbiological or clinical outcomes. Pharmacometric modeling and simulation approaches facilitate quantitative evaluation and optimization of treatment strategies. National and international collaborations and platforms are essential to standardize and harmonize not only studies and models but also monitoring and dosing strategies. Simple bedside decision tools assist clinical pharmacologists and neonatologists in their efforts to fine-tune and personalize the use of primarily renally eliminated antibiotics in term and preterm neonates.
AuthorsMélanie Wilbaux, Aline Fuchs, Janko Samardzic, Frédérique Rodieux, Chantal Csajka, Karel Allegaert, Johannes N van den Anker, Marc Pfister
JournalJournal of clinical pharmacology (J Clin Pharmacol) Vol. 56 Issue 8 Pg. 909-35 (08 2016) ISSN: 1552-4604 [Electronic] England
PMID26766774 (Publication Type: Journal Article, Review)
Copyright© 2016, The American College of Clinical Pharmacology.
Chemical References
  • Anti-Bacterial Agents
Topics
  • Age Factors
  • Anti-Bacterial Agents (administration & dosage, pharmacokinetics)
  • Dose-Response Relationship, Drug
  • Humans
  • Infant, Newborn
  • Infant, Premature (metabolism)
  • Models, Biological
  • Precision Medicine (methods, trends)
  • Renal Elimination (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: